Merck KGaA v. Integra Lifesciences I, Ltd.
The Court ruled that a federal safe harbor protecting drug-related research from patent infringement claims covers early-stage lab testing on patented compounds, even if that particular compound is never actually submitted to the FDA and even if the test results themselves never make it into an FDA filing.
The decision broadens the shield drug companies have when running preliminary experiments while hunting for a viable drug candidate, and it sends the underlying infringement case back for another look under the correct legal standard.
How it got here: A jury found infringement and awarded damages; the trial court upheld the verdict; the Federal Circuit affirmed that ruling, and the funding company asked the Supreme Court to review it.
The Case in Depth
What happened
A German pharmaceutical company funded angiogenesis research at the Scripps Research Institute, where scientists tested patented RGD peptides — owned by Integra Lifesciences and the Burnham Institute — in animal experiments exploring whether blocking certain cell receptors could shrink tumors. Integra sued, claiming the funding company infringed its patents by supplying the peptides for that research, and a jury awarded Integra $15 million in damages.
The question before the Court
Can drug companies use someone else's patented compounds in early lab research aimed at eventually seeking FDA approval, without it counting as patent infringement?
The Court's answer
Yes — the Court ruled that the FDA-research safe harbor in federal patent law protects companies using someone else's patented compounds in early lab experiments, even when the tested compound never itself becomes the subject of an FDA filing and even when the specific experiment's results aren't included in that filing.
The safe harbor applies as long as there's a reasonable basis to believe the compound could eventually be submitted to the FDA and that the experiments will generate the kinds of data relevant to that process. The Federal Circuit had applied a narrower rule, so the Court sent the case back for the evidence to be reassessed under this broader standard.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Pharmaceutical and biotech companies doing early drug-discovery research can rely on a broader legal shield when using patented compounds owned by competitors, without automatically owing royalties or facing infringement suits, so long as the work is reasonably aimed at generating data useful to the FDA approval process.
What changes now
The case goes back to the lower courts so the evidence from the original trial can be reevaluated under the broader legal standard the Supreme Court laid out, rather than the narrower one the Federal Circuit had applied. This is a final ruling on the meaning of the statute, but it does not resolve whether the funding company's specific research activities ultimately qualify for the safe harbor — that determination still has to be made on remand.
What this does not decide
The Court did not decide whether the funding company's specific experiments actually qualify for the safe harbor — it only clarified the legal test. It also expressly declined to address whether the exemption covers use of patented "research tools," since that issue wasn't at stake in this case.
How the Court got there
The legal reasoning, step by step
- The Court read the patent-infringement safe harbor in 35 U.S.C. §271(e)(1) — which exempts uses of patented inventions 'reasonably related to the development and submission of information' to the FDA — as covering any research reasonably tied to generating information for that federal regulatory process, not just research tied to one particular type of FDA filing.
- Because federal drug regulations require companies to submit preclinical animal-testing data covering not just safety but also a drug's efficacy, mechanism of action, and pharmacology, the Court reasoned the safe harbor must cover preclinical studies exploring those characteristics too, not just safety testing.
- The Court rejected the Federal Circuit's narrower reading, which would have limited the safe harbor to research on a compound that itself ends up in an FDA application — reasoning that drug development is trial-and-error, so a rule requiring a compound to already be a known future FDA candidate would effectively limit protection to generic-drug research alone.
- The Court likewise rejected the idea that using a patented compound in an experiment loses safe-harbor protection whenever that specific experiment's results are not included in the eventual FDA submission, since companies often cannot know in advance exactly which data the FDA will need.
- The Court concluded that the safe harbor protects use of a patented compound in preclinical research as long as there is a reasonable basis to think the compound could become the subject of an FDA submission and that the experiments will generate the kinds of information relevant to that submission.
- Because the Federal Circuit had rejected the funding company's evidence challenge under a legal standard narrower than this one, the Court held that the trial evidence still needed to be reviewed under the correct, broader standard.
Doctrinal impact
Cases affected by this decision
Reaffirms Eli Lilly & Co. v. Medtronic, Inc. (496 U. S. 661)
The Court relied on this earlier ruling's refusal to limit the safe harbor to only certain types of FDA submissions.